Texas Senate Bill SB883

Texas 2025 - 89th Regular

• Filed: 1/23/25
• Out of Senate Committee: 4/7/25
• Voted on by Senate: 4/10/25

Caption

Relating to patient access to prescription drugs for off-label use for COVID-19 treatment.

Impact

If enacted, SB 883 would significantly alter existing laws related to medical practice by limiting state interference in the prescribing practices of physicians treating COVID-19 patients. The bill not only empowers physicians but also ensures that they are protected from adverse actions against their medical licenses when prescribing off-label medications, as long as their treatment adheres to established medical standards of care. This encourages a more flexible and responsive approach to patient treatment during health crises.

Summary

Senate Bill 883, titled the Right to Treat Act, aims to enhance patient access to prescription drugs specifically for off-label use in the treatment of COVID-19. The bill recognizes the value of the physician-patient relationship and addresses the frustrations experienced by patients during the COVID-19 pandemic when physicians faced discouragement in prescribing drugs off-label that could potentially benefit their treatment. The proposed legislation supports the autonomy of physicians to prescribe FDA-approved drugs as necessary without facing penalties or restrictions from the state.

Sentiment

The sentiment surrounding SB 883 appears to be generally positive among proponents who view it as a necessary measure for ensuring patient rights and physician discretion in prescribing practices. Supporters argue that it acknowledges the need for practitioners to make individualized treatment decisions without fear of reprisal from state authorities. However, there may also be contention regarding the implications of allowing off-label prescriptions, particularly around concerns of safety and efficacy, as some critics might worry about the potential risks of unregulated off-label drug use.

Contention

Notable points of contention likely stem from the implications of allowing greater leniency in off-label prescribing. Critics may express concerns regarding the safety and accountability associated with such practices, fearing that it could lead to misuse or patient harm. The bill does not create new liabilities for drug manufacturers or prescribing physicians for off-label adverse outcomes, which may raise eyebrows among those advocating for stricter oversight of drug use and prescribing protocols within medical practices.

Texas Constitutional Statutes Affected

Occupations Code

• Chapter 164. Disciplinary Actions And Procedures
  • Section: New Section
  • Section: New Section
  • Section: New Section
  • Section: New Section